New York, New York (PRWEB) June 14, 2014
As the litigation surrounding vaginal mesh complications (http://www.transvaginalmeshlawsuithelp.com/transvaginal-mesh-complications/) allegedly caused by devices used to treat pelvic organ prolapse and stress urinary incontinence continues to grow, Bernstein Liebhard LLP notes that the Illinois Attorney General has been asked to investigate Johnson & Johnson’s marketing of such products. According to a report published by the Journal-Courier on June 13, 2014, a group of women who were allegedly harmed by pelvic mesh devices manufactured by Johnson & Johnson’s Ethicon unit claim that the company may have violated the Uniform Deceptive Trade Practices Act for Illinois by, among other things, allegedly concealing knowledge regarding the risks potentially associated with transvaginal mesh.*
“The issuance of this letter comes as thousands of women pursue transvaginal mesh lawsuits in courts around the country that also accuse Ethicon and Johnson & Johnson of failing to provide adequate warnings about the dangers possibly associated with their pelvic mesh products,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is representing numerous women in Ethicon transvaginal mesh lawsuits that are now pending in state and federal courts, and continues to evaluate legal claims on behalf of others who were allegedly harmed by these devices.
Transvaginal Mesh Lawsuits
Court documents indicate that more than 18,000 transvaginal mesh lawsuits have been filed against Ethicon and Johnson & Johnson in a federal multidistrict litigation underway in U.S. District Court, Southern District of West Virginia. (MDL No. 2327) More than 5,000 additional cases are also pending in a multicounty litigation underway in New Jersey’s Atlantic County Superior Court. All of the lawsuits seek compensation for women who have suffered mesh erosion, pain, scarring, organ damage and other vaginal mesh complications allegedly caused by the defective design and manufacture of Ethicon’s pelvic mesh products. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10).
Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs’ Steering Committee in the federal Ethicon litigation. He was also named Co-Liaison Counsel in the New Jersey proceeding, and served on the Plaintiff’s trial team for its first trial. That case ended in March 2013 with a jury awarding $11 million in compensatory and punitive damages to a woman who suffered vaginal mesh complications related to the Ethicon Gynecare Prolift device. (Gross v. Gynecare Inc., Atl-L-6966-10).
In addition to his work on the Ethicon proceedings, Mr. Grand serves on the Plaintiffs’ Steering Committees for several other vaginal mesh litigations underway in West Virginia federal court, including those involving transvaginal mesh lawsuits filed against American Medical Systems, Inc. (MDL No. 2325); Boston Scientific Corp., (MDL No. 2326); and C.R. Bard, Inc., (MDL No. 2187). Mr. Grand is also serving as Co-Liaison Counsel in a second proceeding involving C.R. Bard devices that is moving forward in Atlantic County Superior Court. (In re: Pelvic Mesh Litigation/Bard, No. L-6339-10.)
Alleged victims of serious vaginal mesh complications may be eligible to file their own transvaginal mesh lawsuit. To learn more, please visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*myjournalcourier.com/news/business-health-news/1426011/State-asked-to-investigate-pelvic-mesh-implants, Journal-Courier, June 13, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP